Integrated needle-free injection and sensing using opto-microfluidicsbroad
iSENS · Horizon Europe grant · 2024-07-01–2027-06-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-TRANSITION-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2023-TRANSITIONOPEN-01. CORDIS record →
Objective
Needle-based injections have revolutionised healthcare by providing an efficient delivery method for medications, such as vaccines. However, there are significant drawbacks associated with using needles on a societal, environmental, and technological level. Needle phobia and infection risks can significantly impact patient compliance and safety with medical treatments, while millions of used needles contaminate the environment every day. Lastly, the effectiveness of certain drugs increases when injected intradermally, but targeting the dermis is challenging.With iSENS, we want to revolutionise the experience of people who receive and perform frequent injections. To this end, we are developing and commercialising a portable and needle-free injector called BoldJet. Our technological breakthrough is threefold:Needle-Free Injection Breakthrough: We introduce an innovative needle-free injection technology, globally pioneering the use of thermocavitation microjets. Our system excels in the precise and consistent delivery of liquids into the skin's superficial layers, surpassing current state-of-the-art methods. Smart Sensing Capability: The BoldJet device will incorporate cutting-edge sensing technology, enabling it to assess the unique properties of the patient's skin before each injection. This breakthrough allows for semi-automatic calibration, tailoring the injection parameters to the specific skin type and treatment area. Real-Time Monitoring and Precision: BoldJet goes beyond conventional methods by offering real-time monitoring of injection depth and volume. This feature guarantees that each dose is administered accurately and consistently.With our triple technology platform, we will offer a safer, more effective, and minimally invasive injections that do not contaminate our environment. This patient-friendly technology will result in a positive effect on society, allowing millions of people to receive better and more personalised healthcare.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| FLOWBEAMS BV | NL | coordinator | €2,499,999 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.